Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.50
EXAC's Cash to Debt is ranked lower than
74% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. EXAC: 0.50 )
Ranked among companies with meaningful Cash to Debt only.
EXAC' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.19 Max: No Debt
Current: 0.5
Equity to Asset 0.81
EXAC's Equity to Asset is ranked higher than
80% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. EXAC: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
EXAC' s Equity to Asset Range Over the Past 10 Years
Min: 0.59  Med: 0.73 Max: 0.88
Current: 0.81
0.59
0.88
Interest Coverage 18.20
EXAC's Interest Coverage is ranked lower than
67% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 69.16 vs. EXAC: 18.20 )
Ranked among companies with meaningful Interest Coverage only.
EXAC' s Interest Coverage Range Over the Past 10 Years
Min: 6.39  Med: 16.85 Max: 28.71
Current: 18.2
6.39
28.71
F-Score: 3
Z-Score: 6.52
M-Score: -2.60
WACC vs ROIC
7.21%
6.89%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 9.20
EXAC's Operating margin (%) is ranked higher than
68% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. EXAC: 9.20 )
Ranked among companies with meaningful Operating margin (%) only.
EXAC' s Operating margin (%) Range Over the Past 10 Years
Min: 6.73  Med: 9.88 Max: 13.6
Current: 9.2
6.73
13.6
Net-margin (%) 6.30
EXAC's Net-margin (%) is ranked higher than
66% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.24 vs. EXAC: 6.30 )
Ranked among companies with meaningful Net-margin (%) only.
EXAC' s Net-margin (%) Range Over the Past 10 Years
Min: 4.3  Med: 6.3 Max: 7.57
Current: 6.3
4.3
7.57
ROE (%) 6.89
EXAC's ROE (%) is ranked higher than
62% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. EXAC: 6.89 )
Ranked among companies with meaningful ROE (%) only.
EXAC' s ROE (%) Range Over the Past 10 Years
Min: 5.87  Med: 7.99 Max: 10.86
Current: 6.89
5.87
10.86
ROA (%) 5.58
EXAC's ROA (%) is ranked higher than
69% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. EXAC: 5.58 )
Ranked among companies with meaningful ROA (%) only.
EXAC' s ROA (%) Range Over the Past 10 Years
Min: 3.9  Med: 5.78 Max: 7.81
Current: 5.58
3.9
7.81
ROC (Joel Greenblatt) (%) 12.34
EXAC's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 4.17 vs. EXAC: 12.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EXAC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 9.09  Med: 13.13 Max: 18.6
Current: 12.34
9.09
18.6
Revenue Growth (3Y)(%) -1.10
EXAC's Revenue Growth (3Y)(%) is ranked lower than
67% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. EXAC: -1.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EXAC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.1  Med: 14.2 Max: 30.5
Current: -1.1
-1.1
30.5
EBITDA Growth (3Y)(%) -2.00
EXAC's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. EXAC: -2.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EXAC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -2  Med: 12.1 Max: 38
Current: -2
-2
38
EPS Growth (3Y)(%) 2.70
EXAC's EPS Growth (3Y)(%) is ranked higher than
50% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. EXAC: 2.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EXAC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.3  Med: 13.5 Max: 34.6
Current: 2.7
-8.3
34.6
» EXAC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

EXAC Guru Trades in Q3 2015

Jim Simons 66,500 sh (+23.84%)
Mario Gabelli 639,479 sh (-1.11%)
Chuck Royce 667,856 sh (-6.54%)
» More
Q4 2015

EXAC Guru Trades in Q4 2015

Jim Simons 79,400 sh (+19.40%)
Mario Gabelli 649,279 sh (+1.53%)
Chuck Royce 596,546 sh (-10.68%)
» More
Q1 2016

EXAC Guru Trades in Q1 2016

Jim Simons 90,800 sh (+14.36%)
Mario Gabelli 666,009 sh (+2.58%)
Chuck Royce 409,474 sh (-31.36%)
» More
Q2 2016

EXAC Guru Trades in Q2 2016

Jeremy Grantham 9,121 sh (New)
Mario Gabelli 665,609 sh (-0.06%)
Jim Simons 90,100 sh (-0.77%)
Chuck Royce 322,320 sh (-21.28%)
» More
» Details

Insider Trades

Latest Guru Trades with EXAC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:IVC, NAS:XENT, NAS:ARAY, NAS:GNMK, OTCPK:MZRTF, NAS:AXGN, NAS:TNDM, NAS:ELOS, OTCPK:XVIPF, OTCPK:VICA, NAS:PAVM, NAS:IRMD, NAS:VRAY, NAS:RTIX, NYSE:CRY, NAS:ACRX, OTCPK:SBMAF, NAS:CUTR, OTCPK:SOMNF, NAS:IRIX » details
Exactech Inc develops, manufactures, markets, distributes and sells orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally.

Exactech Inc was founded by an orthopaedic surgeon in November 1985, and is incorporated under the laws of the State of Florida. The Company develops, manufactures, markets, distributes and sella orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally. Its U.S. sales and distribution activities are conducted by its wholly owned subsidiary Exactech U.S., Inc. The Companys international development, sales and distribution activities are conducted by its wholly owned subsidiary Exactech International Operations, AG based in Bern, Switzerland. The Company manufactures some components of its knee, extremity, and hip joint replacement systems at its facility in Gainesville, Florida, utilizing modern, automated computer aided manufacturing equipment. Its cellular based manufacturing processes, which are organized in groups, or cells, are dedicated to specific product lines to minimize change-over and increase efficiency. To supplement its manufacturing of components, the company has formed strategic alliances with suppliers and business partners to externally manufacture some components. Additionally, the company acquires and distribute other products and services through exclusive agreements, such as its agreement with Tecres S.p.A, (Tecres) and Blue Ortho, SAS (Blue Ortho), and non-exclusive agreements, such as with RTI Surgical, Inc., (RTI), and Biomatlante SARL, (Biomatlante). The company markets its orthopaedic implant products in the United States through Exactech U.S., Inc. that operates through a network of independent sales agencies and direct sales representatives. The company offers its products in all fifty states, Puerto Rico, and the District of Columbia. The Companys competitors in the orthopaedic market are DePuy, Inc., a division of Johnson and Johnson, Zimmer, Inc., a subsidiary of Zimmer Holdings, Inc., Stryker Corporation, Smith and Nephew plc, and Biomet, Inc. The Companys operations are subject to numerous and increasingly stringent federal, state and local environmental laws and regulations in the United States and other countries in which operates.

Guru Investment Theses on Exactech Inc

Meridian Funds Comments on Exact Sciences Corp - Mar 08, 2016

Exact Sciences Corp. (NASDAQ:EXAC) declined after an independent panel of health care experts excluded the company’s colon cancer-screening test from a list of recommended tests in the U.S. Instead, the panel defined the product as “alternative testing that may be useful in select clinical circumstances.” Marketed as Cologuard, the product is a non-invasive, FDA-approved colorectal cancer-screening test covered by Medicare. It has proven effective at detecting early-stage colon cancer as well as precancerous lesions. When detected early, colon cancer is highly curable. However, Cologuard’s exclusion from the panel’s list of recommended tests may make it more difficult to win favorable reimbursement from private insurers. We consequently liquidated our position in Exact Sciences and used proceeds from the sale to invest in other, more attractive investment opportunities.





From the Meridian Equity Income Fund fourth quarter commentary.



Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 23.57
EXAC's P/E(ttm) is ranked higher than
54% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 27.08 vs. EXAC: 23.57 )
Ranked among companies with meaningful P/E(ttm) only.
EXAC' s P/E(ttm) Range Over the Past 10 Years
Min: 13.63  Med: 21.57 Max: 36.46
Current: 23.57
13.63
36.46
Forward P/E 20.88
EXAC's Forward P/E is ranked higher than
64% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 23.87 vs. EXAC: 20.88 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.57
EXAC's PE(NRI) is ranked higher than
55% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 27.22 vs. EXAC: 23.57 )
Ranked among companies with meaningful PE(NRI) only.
EXAC' s PE(NRI) Range Over the Past 10 Years
Min: 13.63  Med: 21.57 Max: 36.46
Current: 23.57
13.63
36.46
P/B 1.55
EXAC's P/B is ranked higher than
78% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. EXAC: 1.55 )
Ranked among companies with meaningful P/B only.
EXAC' s P/B Range Over the Past 10 Years
Min: 1.06  Med: 1.57 Max: 3.48
Current: 1.55
1.06
3.48
P/S 1.47
EXAC's P/S is ranked higher than
67% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. EXAC: 1.47 )
Ranked among companies with meaningful P/S only.
EXAC' s P/S Range Over the Past 10 Years
Min: 0.85  Med: 1.26 Max: 2.58
Current: 1.47
0.85
2.58
POCF 16.45
EXAC's POCF is ranked higher than
58% of the 132 Companies
in the Global Medical Devices industry.

( Industry Median: 21.53 vs. EXAC: 16.45 )
Ranked among companies with meaningful POCF only.
EXAC' s POCF Range Over the Past 10 Years
Min: 7.49  Med: 11.19 Max: 49.48
Current: 16.45
7.49
49.48
EV-to-EBIT 16.02
EXAC's EV-to-EBIT is ranked higher than
63% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 22.51 vs. EXAC: 16.02 )
Ranked among companies with meaningful EV-to-EBIT only.
EXAC' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 14.4 Max: 21.6
Current: 16.02
9.2
21.6
EV-to-EBITDA 9.05
EXAC's EV-to-EBITDA is ranked higher than
75% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 16.88 vs. EXAC: 9.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
EXAC' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6  Med: 8.5 Max: 15
Current: 9.05
6
15
PEG 4.83
EXAC's PEG is ranked lower than
67% of the 75 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. EXAC: 4.83 )
Ranked among companies with meaningful PEG only.
EXAC' s PEG Range Over the Past 10 Years
Min: 1.17  Med: 2.47 Max: 5.13
Current: 4.83
1.17
5.13
Shiller P/E 27.33
EXAC's Shiller P/E is ranked higher than
81% of the 47 Companies
in the Global Medical Devices industry.

( Industry Median: 42.11 vs. EXAC: 27.33 )
Ranked among companies with meaningful Shiller P/E only.
EXAC' s Shiller P/E Range Over the Past 10 Years
Min: 17.96  Med: 25.39 Max: 51.8
Current: 27.33
17.96
51.8
Current Ratio 4.68
EXAC's Current Ratio is ranked higher than
74% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. EXAC: 4.68 )
Ranked among companies with meaningful Current Ratio only.
EXAC' s Current Ratio Range Over the Past 10 Years
Min: 2.14  Med: 4.51 Max: 8.35
Current: 4.68
2.14
8.35
Quick Ratio 2.24
EXAC's Quick Ratio is ranked higher than
55% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 1.94 vs. EXAC: 2.24 )
Ranked among companies with meaningful Quick Ratio only.
EXAC' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 2.04 Max: 5.2
Current: 2.24
0.59
5.2
Days Inventory 347.53
EXAC's Days Inventory is ranked lower than
90% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 132.35 vs. EXAC: 347.53 )
Ranked among companies with meaningful Days Inventory only.
EXAC' s Days Inventory Range Over the Past 10 Years
Min: 330.22  Med: 349.35 Max: 363.57
Current: 347.53
330.22
363.57
Days Sales Outstanding 78.93
EXAC's Days Sales Outstanding is ranked lower than
60% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 68.07 vs. EXAC: 78.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXAC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 62.45  Med: 75.41 Max: 91
Current: 78.93
62.45
91
Days Payable 76.01
EXAC's Days Payable is ranked higher than
61% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.81 vs. EXAC: 76.01 )
Ranked among companies with meaningful Days Payable only.
EXAC' s Days Payable Range Over the Past 10 Years
Min: 52.26  Med: 75.56 Max: 90.48
Current: 76.01
52.26
90.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
EXAC's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. EXAC: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EXAC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.9  Med: -1.5 Max: -1
Current: -2
-3.9
-1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 4.32
EXAC's Price/Net Current Asset Value is ranked higher than
68% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 7.11 vs. EXAC: 4.32 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EXAC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.87  Med: 4.69 Max: 18.45
Current: 4.32
1.87
18.45
Price/Tangible Book 1.83
EXAC's Price/Tangible Book is ranked higher than
81% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 4.42 vs. EXAC: 1.83 )
Ranked among companies with meaningful Price/Tangible Book only.
EXAC' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.26  Med: 2.1 Max: 4.7
Current: 1.83
1.26
4.7
Price/Projected FCF 1.91
EXAC's Price/Projected FCF is ranked higher than
56% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. EXAC: 1.91 )
Ranked among companies with meaningful Price/Projected FCF only.
EXAC' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.25  Med: 3.16 Max: 383
Current: 1.91
0.25
383
Price/DCF (Earnings Based) 2.01
EXAC's Price/DCF (Earnings Based) is ranked lower than
56% of the 18 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. EXAC: 2.01 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.18
EXAC's Price/Median PS Value is ranked lower than
61% of the 253 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. EXAC: 1.18 )
Ranked among companies with meaningful Price/Median PS Value only.
EXAC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.71  Med: 1.3 Max: 2.62
Current: 1.18
0.71
2.62
Price/Graham Number 1.39
EXAC's Price/Graham Number is ranked higher than
67% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. EXAC: 1.39 )
Ranked among companies with meaningful Price/Graham Number only.
EXAC' s Price/Graham Number Range Over the Past 10 Years
Min: 0.89  Med: 1.43 Max: 2.73
Current: 1.39
0.89
2.73
Earnings Yield (Greenblatt) (%) 6.26
EXAC's Earnings Yield (Greenblatt) (%) is ranked higher than
81% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. EXAC: 6.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EXAC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.6  Med: 7 Max: 10.8
Current: 6.26
4.6
10.8
Forward Rate of Return (Yacktman) (%) 6.16
EXAC's Forward Rate of Return (Yacktman) (%) is ranked lower than
55% of the 118 Companies
in the Global Medical Devices industry.

( Industry Median: 7.67 vs. EXAC: 6.16 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
EXAC' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.7  Med: 9.35 Max: 14
Current: 6.16
3.7
14

More Statistics

Revenue (TTM) (Mil) $250.4
EPS (TTM) $ 1.11
Beta0.76
Short Percentage of Float2.61%
52-Week Range $16.11 - 28.66
Shares Outstanding (Mil)14.15

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 257 272 285 305
EPS ($) 1.16 1.32 1.47 1.60
EPS w/o NRI ($) 1.16 1.32 1.47 1.60
EPS Growth Rate
(3Y to 5Y Estimate)
10.90%
Dividends Per Share ($)
» More Articles for EXAC

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Exact Sciences Corp Mar 08 2016 
What the Gurus Did This Week - Weekly Update on Guru Real Time Activity Jun 28 2013 
Mario Gabelli Ups His Holdings in EXAC, TWIN and LAYN Jun 28 2013 
Exactech Inc. Reports Operating Results (10-K) Mar 16 2011 
Exactech Inc. Reports Operating Results (10-Q) Nov 09 2010 
Chuck Royce’s Top Predictable Companies: MEDNAX, Techne Corp., ITT Educational Services, Exactech May 17 2010 
Exactech Inc. Reports Operating Results (10-Q) May 05 2010 
Exactech Inc. (EXAC) CFO and Treasurer Joel C Phillips sells 2,497 Shares May 04 2010 
Exactech Inc. (EXAC) CEO and Chairman, 10% Owner R William Petty sells 20,000 Shares Dec 11 2009 
Exactech Inc. Reports Operating Results (10-Q) Nov 05 2009 

More From Other Websites
4:26 pm Exactech announces 'positive surgeon feedback on first surgeries performed with the... Sep 29 2016
Exactech Announces Successful First Surgeries with New ExactechGPS® Total Shoulder Application Sep 29 2016
Exactech, Inc. breached its 50 day moving average in a Bearish Manner : EXAC-US : September 27, 2016 Sep 27 2016
Statement - H1 2016 results Sep 23 2016
Exactech, Inc. – Value Analysis (NASDAQ:EXAC) : September 14, 2016 Sep 14 2016
Exactech, Inc. breached its 50 day moving average in a Bullish Manner : EXAC-US : September 13, 2016 Sep 13 2016
Exactech Announces Investor Presentation at Baird Global Healthcare Conference Sep 06 2016
ETF’s with exposure to Exactech, Inc. : September 1, 2016 Sep 01 2016
This Little-Known Orthopedic-Device Stock Is Delivering Huge Returns Aug 29 2016
EXACTECH INC Financials Aug 18 2016
Exactech, Inc. :EXAC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 Aug 10 2016
EXACTECH INC Files SEC form 10-Q, Quarterly Report Aug 09 2016
Exacompta Clairefontaine SA :EXAC-FR: Earnings Analysis: For the six months ended December 31, 2015... Aug 08 2016
Exactech (EXAC) Beats Earnings on Higher Revenues in Q2 Aug 03 2016
Edited Transcript of EXAC earnings conference call or presentation 2-Aug-16 2:00pm GMT Aug 02 2016
EXACTECH INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 01 2016
Exactech posts 2Q profit Aug 01 2016
Exactech posts 2Q profit Aug 01 2016
Exactech Q2 Revenue Up 8% to $66.1 Million; Net Income up 20% to $4.4 Million; Diluted EPS $0.31 vs.... Aug 01 2016
Q2 2016 Exactech Inc Earnings Release - After Market Close Aug 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)